
Nektar’s stock doubles on eczema therapy success in Phase IIb study
Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin (rezpeg) successfully met its primary and key secondary endpoints. The US-based biotech reported a statistically significant …